1. S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB. (23rd June 2022) Authors: Kim, D.; Atenafu, E.; Forrest, D.; Bence-Bruckler, I.; Savoie, L.; Keating, M.-M.; Busque, L.; Delage, R.; Xenocostas, A.; Liew, E.; Laneuville, P.; Paulson, K.; Stockley, T.; Lipton, J.; Leber, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT. (23rd June 2022) Authors: Busque, L.; Harnois, M.; Szuber, N.; Delage, R.; Mollica, L.; Olney, H.; Laneuville, P.; Sirhan, S.; Cournoyer, G.; Chamakhi, I.; Lalancette, M.; Talbot, D.; Éthier, V.; Desjardins, P.; Assouline, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SPIReL: PHASE 2 STUDY DPX‐SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Berinstein, N.L.; Bence‐Buckler, I.A.; Laneuville, P.; Stewart, D.; Smyth, L.; Kerr, C.; Klein, G.; Pennell, N.; Roos‐Assar, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 569 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗